Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29540998
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Bench to bedside review of myositis autoantibodies
#MMPMID29540998
Palterer B
; Vitiello G
; Carraresi A
; Giudizi MG
; Cammelli D
; Parronchi P
Clin Mol Allergy
2018[]; 16
(?): 5
PMID29540998
show ga
Idiopathic inflammatory myopathies represent a heterogeneous group of autoimmune
diseases with systemic involvement. Even though numerous specific autoantibodies
have been recognized, they have not been included, with the only exception of
anti-Jo-1, into the 2017 Classification Criteria, thus perpetuating a
clinical-serologic gap. The lack of homogeneous grouping based on the antibody
profile deeply impacts the diagnostic approach, therapeutic choices and
prognostic stratification of these patients. This review is intended to highlight
the comprehensive scenario regarding myositis-related autoantibodies, from the
molecular characterization and biological significance to target antigens, from
the detection tools, with a special focus on immunofluorescence patterns on HEp-2
cells, to their relative prevalence and ethnic diversity, from the clinical
presentation to prognosis. If, on the one hand, a notable body of literature is
present, on the other data are fragmented, retrospectively based and collected
from small case series, so that they do not sufficiently support the
decision-making process (i.e. therapeutic approach) into the clinics.
free
free
free
